カテゴリー： IMARC, 世界, 医療/バイオ

中枢神経系（CNS）治療の世界市場2023-2028：産業動向、シェア、規模、成長、機会・予測

◆英語タイトル：Central Nervous System (CNS) Therapeutics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028

IMARCが発行した調査報告書（IMARC23AP141）◆商品コード：IMARC23AP141
◆発行会社（リサーチ会社）：IMARC
◆発行日：2023年3月2日
◆ページ数：142
◆レポート形式：英語 / PDF
◆納品方法：Eメール
◆調査対象地域：グローバル
◆産業分野：医療
◆販売価格オプション（消費税別）
Single UserUSD2,999 ⇒換算￥455,848見積依頼/購入/質問フォーム
Five UserUSD3,999 ⇒換算￥607,848見積依頼/購入/質問フォーム
EnterprisewideUSD4,999 ⇒換算￥759,848見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

アイマーク社の本調査資料によると、2022年に1,312億ドルであった世界の中枢神経系（CNS）治療市場規模が、2028年までに2,146億ドルとなり、予測期間中にCAGR6.8%で拡大すると見込まれています。本書は、中枢神経系（CNS）治療の世界市場を徹底的に分析し、市場の現状や今後の動向をまとめた資料です。序論、範囲・調査手法、エグゼクティブサマリー、イントロダクション、疾患別（神経変性疾患、神経血管系疾患、中枢神経系外傷、メンタルヘルス、その他）分析、用途別（病院、クリニック、在宅治療、その他）分析、地域別（北米、アジア太平洋、ヨーロッパ、中南米、中東・アフリカ）分析、SWOT分析、バリューチェーン分析、ポーターズファイブフォース分析、価格分析、競争状況など、以下の構成で掲載しています。また、本書内には、AstraZeneca plc、Biogen Inc.、Eli Lilly and Company、F. Hoffmann-La Roche AG (Roche Holding)、H. Lundbeck A/S、Merck & Co. Inc.、Neurocrine Biosciences Inc.、Novartis AG、Pfizer Inc.、Sanofi S.A.、Takeda Pharmaceutical Company Limited and Teva Pharmaceutical Industries Ltd.など、参入企業情報が含まれています。
・序論
・範囲・調査手法
・エグゼクティブサマリー
・イントロダクション
・世界の中枢神経系（CNS）治療市場規模：疾患別
- 神経変性疾患の市場規模
- 神経血管系疾患の市場規模
- 中枢神経系外傷の市場規模
- メンタルヘルスの市場規模
- その他の市場規模
・世界の中枢神経系（CNS）治療市場規模：用途別
- 病院における市場規模
- クリニックにおける市場規模
- 在宅治療における市場規模
- その他における市場規模
・世界の中枢神経系（CNS）治療市場規模：地域別
- 北米の中枢神経系（CNS）治療市場規模
- アジア太平洋の中枢神経系（CNS）治療市場規模
- ヨーロッパの中枢神経系（CNS）治療市場規模
- 中南米の中枢神経系（CNS）治療市場規模
- 中東・アフリカの中枢神経系（CNS）治療市場規模
・SWOT分析
・バリューチェーン分析
・ポーターズファイブフォース分析
・価格分析
・競争状況

The global central nervous system (CNS) therapeutics market size reached US$ 131.2 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 214.6 Billion by 2028, exhibiting a growth rate (CAGR) of 6.8% during 2023-2028.

The central nervous system (CNS) represents a vital part of the nervous system that comprises of the brain and the spinal cord. It integrates the received information, thereafter coordinating and controlling the activities of all parts of the body. CNS therapeutics primarily include anesthetics, anticonvulsants, CNS stimulants, muscle relaxants, narcotic analgesics, sedatives, etc. They are widely adopted in the treatment procedures of Parkinson’s disease, depression, Alzheimer’s disease, epilepsy, traumatic brain, spinal cord injury, CNS cancer, etc.

Central Nervous System (CNS) Therapeutics Market Trends:
The elevating prevalence of mental illness and lifestyle-associated CNS disorders, including anxiety, depression, hypertension, etc., is primarily driving the global CNS therapeutics market. In line with this, the growing geriatric population, who are more prone to chronic neurological ailments such as Alzheimer’s disease and Parkinson’s disease, is also propelling the global market. Additionally, the emerging popularity of generic neurologic drugs across developing countries on account of their affordability is further augmenting the market for CNS therapeutics. Apart from this, continuous innovations in CNS treatment procedures, such as the development of gene therapy, neurostimulation tools, and neural transplantation techniques, are also stimulating the market growth. These approaches prolong the action of unremitting dopaminergic stimulation medicines and control disease progression. Moreover, the introduction of novel drug-delivery systems that provide ease of administration and availability of different dosage forms is further creating a positive outlook for the global CNS market. For instance, transdermal patches are gaining traction in the field of neurology to treat CNS disorders as they offer a precise amount of medicine and relief for around 24 hours. Besides this, the increasing focus of the government and non-government organizations on creating awareness regarding numerous CNS disorders and the accessibility to multiple treatment options is also catalyzing the market growth. Moreover, the launch of favorable guidelines to support faster approvals of pipeline drugs for neurodegenerative diseases and clinical trials that encourage the entry of new products is expected to drive the global central nervous system therapeutics market in the coming years.

Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global central nervous system (CNS) therapeutics market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on disease and application.

Breakup by Disease:
Neurodegenerative Diseases
Alzheimer’s Disease
Parkinson’s Disease
Multiple Sclerosis
Huntington’s Disease
Amyotrophic Lateral Sclerosis
Others
Neurovascular Diseases
CNS Trauma
Mental Health
Anxiety Disorders
Epilepsy
Mood Disorders
Psychotic Disorders
Others
Infectious Diseases
CNS Cancer
Others

Breakup by Application:
Hospital
Clinic
Homecare
Others

Breakup by Region:
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa

Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being AstraZeneca plc, Biogen Inc., Eli Lilly and Company, F. Hoffmann-La Roche AG (Roche Holding), H. Lundbeck A/S, Merck & Co. Inc., Neurocrine Biosciences Inc., Novartis AG, Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited and Teva Pharmaceutical Industries Ltd.

Key Questions Answered in This Report
1. What was the size of the global Central Nervous System (CNS) therapeutics market in 2022?
2. What is the expected growth rate of the global Central Nervous System (CNS) therapeutics market during 2023-2028
3. What are the key factors driving the global Central Nervous System (CNS) therapeutics market?
4. What has been the impact of COVID-19 on the global Central Nervous System (CNS) therapeutics market?
5. What is the breakup of the global Central Nervous System (CNS) therapeutics market based on the disease?
6. What are the key regions in the global Central Nervous System (CNS) therapeutics market?
7. Who are the key players/companies in the global Central Nervous System (CNS) therapeutics market?

❖ レポートの目次 ❖

1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Central Nervous System (CNS) Therapeutics Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Disease
6.1 Neurodegenerative Diseases
6.1.1 Market Trends
6.1.2 Key Segments
6.1.2.1 Alzheimer’s Disease
6.1.2.2 Parkinson’s Disease
6.1.2.3 Multiple Sclerosis
6.1.2.4 Huntington’s Disease
6.1.2.5 Amyotrophic Lateral Sclerosis
6.1.2.6 Others
6.1.3 Market Forecast
6.2 Neurovascular Diseases
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 CNS Trauma
6.3.1 Market Trends
6.3.2 Market Forecast
6.4 Mental Health
6.4.1 Market Trends
6.4.2 Key Segments
6.4.2.1 Anxiety Disorders
6.4.2.2 Epilepsy
6.4.2.3 Mood Disorders
6.4.2.4 Psychotic Disorders
6.4.2.5 Others
6.4.3 Market Forecast
6.5 Infectious Diseases
6.5.1 Market Trends
6.5.2 Market Forecast
6.6 CNS Cancer
6.6.1 Market Trends
6.6.2 Market Forecast
6.7 Others
6.7.1 Market Trends
6.7.2 Market Forecast
7 Market Breakup by Application
7.1 Hospital
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Clinic
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Homecare
7.3.1 Market Trends
7.3.2 Market Forecast
7.4 Others
7.4.1 Market Trends
7.4.2 Market Forecast
8 Market Breakup by Region
8.1 North America
8.1.1 United States
8.1.1.1 Market Trends
8.1.1.2 Market Forecast
8.1.2 Canada
8.1.2.1 Market Trends
8.1.2.2 Market Forecast
8.2 Asia-Pacific
8.2.1 China
8.2.1.1 Market Trends
8.2.1.2 Market Forecast
8.2.2 Japan
8.2.2.1 Market Trends
8.2.2.2 Market Forecast
8.2.3 India
8.2.3.1 Market Trends
8.2.3.2 Market Forecast
8.2.4 South Korea
8.2.4.1 Market Trends
8.2.4.2 Market Forecast
8.2.5 Australia
8.2.5.1 Market Trends
8.2.5.2 Market Forecast
8.2.6 Indonesia
8.2.6.1 Market Trends
8.2.6.2 Market Forecast
8.2.7 Others
8.2.7.1 Market Trends
8.2.7.2 Market Forecast
8.3 Europe
8.3.1 Germany
8.3.1.1 Market Trends
8.3.1.2 Market Forecast
8.3.2 France
8.3.2.1 Market Trends
8.3.2.2 Market Forecast
8.3.3 United Kingdom
8.3.3.1 Market Trends
8.3.3.2 Market Forecast
8.3.4 Italy
8.3.4.1 Market Trends
8.3.4.2 Market Forecast
8.3.5 Spain
8.3.5.1 Market Trends
8.3.5.2 Market Forecast
8.3.6 Russia
8.3.6.1 Market Trends
8.3.6.2 Market Forecast
8.3.7 Others
8.3.7.1 Market Trends
8.3.7.2 Market Forecast
8.4 Latin America
8.4.1 Brazil
8.4.1.1 Market Trends
8.4.1.2 Market Forecast
8.4.2 Mexico
8.4.2.1 Market Trends
8.4.2.2 Market Forecast
8.4.3 Others
8.4.3.1 Market Trends
8.4.3.2 Market Forecast
8.5 Middle East and Africa
8.5.1 Market Trends
8.5.2 Market Breakup by Country
8.5.3 Market Forecast
9 SWOT Analysis
9.1 Overview
9.2 Strengths
9.3 Weaknesses
9.4 Opportunities
9.5 Threats
10 Value Chain Analysis
11 Porters Five Forces Analysis
11.1 Overview
11.2 Bargaining Power of Buyers
11.3 Bargaining Power of Suppliers
11.4 Degree of Competition
11.5 Threat of New Entrants
11.6 Threat of Substitutes
12 Price Analysis
13 Competitive Landscape
13.1 Market Structure
13.2 Key Players
13.3 Profiles of Key Players
13.3.1 AstraZeneca plc
13.3.1.1 Company Overview
13.3.1.2 Product Portfolio
13.3.1.3 Financials
13.3.1.4 SWOT Analysis
13.3.2 Biogen Inc.
13.3.2.1 Company Overview
13.3.2.2 Product Portfolio
13.3.2.3 Financials
13.3.2.4 SWOT Analysis
13.3.3 Eli Lilly and Company
13.3.3.1 Company Overview
13.3.3.2 Product Portfolio
13.3.3.3 Financials
13.3.3.4 SWOT Analysis
13.3.4 F. Hoffmann-La Roche AG (Roche Holding)
13.3.4.1 Company Overview
13.3.4.2 Product Portfolio
13.3.4.3 SWOT Analysis
13.3.5 H. Lundbeck A/S
13.3.5.1 Company Overview
13.3.5.2 Product Portfolio
13.3.5.3 Financials
13.3.5.4 SWOT Analysis
13.3.6 Merck & Co. Inc.
13.3.6.1 Company Overview
13.3.6.2 Product Portfolio
13.3.6.3 Financials
13.3.6.4 SWOT Analysis
13.3.7 Neurocrine Biosciences Inc.
13.3.7.1 Company Overview
13.3.7.2 Product Portfolio
13.3.7.3 Financials
13.3.7.4 SWOT Analysis
13.3.8 Novartis AG
13.3.8.1 Company Overview
13.3.8.2 Product Portfolio
13.3.8.3 Financials
13.3.8.4 SWOT Analysis
13.3.9 Pfizer Inc.
13.3.9.1 Company Overview
13.3.9.2 Product Portfolio
13.3.9.3 Financials
13.3.9.4 SWOT Analysis
13.3.10 Sanofi S.A.
13.3.10.1 Company Overview
13.3.10.2 Product Portfolio
13.3.10.3 Financials
13.3.10.4 SWOT Analysis
13.3.11 Takeda Pharmaceutical Company Limited
13.3.11.1 Company Overview
13.3.11.2 Product Portfolio
13.3.11.3 Financials
13.3.11.4 SWOT Analysis
13.3.12 Teva Pharmaceutical Industries Ltd.
13.3.12.1 Company Overview
13.3.12.2 Product Portfolio
13.3.12.3 Financials
13.3.12.4 SWOT Analysis



❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
★リサーチレポート[ 中枢神経系（CNS）治療の世界市場2023-2028：産業動向、シェア、規模、成長、機会・予測(Central Nervous System (CNS) Therapeutics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028)]についてメールでお問い合わせはこちらでお願いします。
◆関連リサーチレポート◆
  • 鎌状赤血球症（SCD）治療の世界市場2023～2028：産業動向、シェア、規模、成長、機会・予測
  • 前立腺肥大症（BPH）治療の世界市場2023～2028：産業動向、シェア、規模、成長、機会・予測
  • 治療用ワクチンの世界市場2022-2028：産業動向、シェア、規模、成長、機会・予測
  • 自己免疫疾患診断の世界市場2023～2028：産業動向、シェア、規模、成長、機会・予測

    • ◆H&Iグローバルリサーチのお客様（例）◆